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MaBACKGROUND Despite endorsement of digoxin in clinical practice guidelines, there exist limited data on its safety in
atrial ﬁbrillation/ﬂutter (AF).
OBJECTIVES The goal of this study was to evaluate the association of digoxin with mortality in AF.
METHODS Using complete data of the TREAT-AF (The Retrospective Evaluation and Assessment of Therapies in AF)
study from the U.S. Department of Veterans Affairs (VA) healthcare system, we identiﬁed patients with newly diagnosed,
nonvalvular AF seen within 90 days in an outpatient setting between VA ﬁscal years 2004 and 2008. We used multi-
variate and propensity-matched Cox proportional hazards to evaluate the association of digoxin use with death. Residual
confounding was assessed by sensitivity analysis.
RESULTS Of 122,465 patients with 353,168 person-years of follow-up (age 72.1  10.3 years, 98.4% male), 28,679
(23.4%) patients received digoxin. Cumulative mortality rates were higher for digoxin-treated patients than for untreated
patients (95 vs. 67 per 1,000 person-years; p < 0.001). Digoxin use was independently associated with mortality after
multivariate adjustment (hazard ratio [HR]: 1.26, 95% conﬁdence interval [CI]: 1.23 to 1.29, p < 0.001) and propensity
matching (HR: 1.21, 95% CI: 1.17 to 1.25, p < 0.001), even after adjustment for drug adherence. The risk of death was not
modiﬁed by age, sex, heart failure, kidney function, or concomitant use of beta-blockers, amiodarone, or warfarin.
CONCLUSIONS Digoxin was associated with increased risk of death in patients with newly diagnosed AF, independent
of drug adherence, kidney function, cardiovascular comorbidities, and concomitant therapies. These ﬁndings challenge
current cardiovascular society recommendations on use of digoxin in AF. (J Am Coll Cardiol 2014;64:660–8) © 2014 by
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ABB R E V I A T I O N S
AND ACRONYMS
AF = atrial ﬁbrillation/atrial
ﬂutter
CI = conﬁdence interval
eGFR = estimated glomerular
ﬁltration rate
HF = heart failure
HR = hazard ratio
ICD-9 = International
Classiﬁcation of Diseases-9th
Revision
IDMS = isotope-dilution mass
spectroscopy
MI = myocardial infarction
MPR = medication possession
ratio
J A C C V O L . 6 4 , N O . 7 , 2 0 1 4 Turakhia et al.
A U G U S T 1 9 , 2 0 1 4 : 6 6 0 – 8 Digoxin and Mortality in AF
661I n atrial ﬁbrillation/atrial ﬂutter (AF, collec-tively), digoxin is one of the most widely usedrate control agents worldwide and is largely
accepted as a valid therapeutic option (1). Clinical
guidelines currently endorse the use of digoxin in
AF, despite the lack of randomized trials of digoxin
in AF cohorts (2,3). In heart failure (HF) cohorts, the
effectiveness and safety of digoxin has been shown
to vary by serum digoxin concentrations (4–6), indi-
cating possible moderation by kidney function (7).
However, despite established arrhythmic and nonar-
rhythmic toxicities, there are only limited, conﬂict-
ing, and mostly older observational data on the
safety of digoxin in AF (8–11). We therefore investi-
gated the association of digoxin therapy with mortal-
ity in a large cohort of patients with newly diagnosed
AF from a large, national healthcare system.SEE PAGE 669
VA = U.S. Department of
Veterans AffairsMETHODS
The TREAT-AF (The Retrospective Evaluation and
Assessment of Therapies in AF) study is a retrospective
cohort study of patients with newly diagnosed AF
treated in the U.S. Department of Veterans Affairs (VA)
healthcare system (12), which is the largest integrated
healthcare system in the United States. We used data
from multiple VA centralized datasets, which repre-
sent claims and electronic health records from the full
denominator of VA users. Linked and merged datasets
include the VA National Patient Care Database, which
contains demographic, outpatient, inpatient, and
long-term care administrative data (13); the VA Deci-
sion Support System national pharmacy extract, which
provides patient-level detail on inpatient and outpa-
tient medications, dispensing details, and costs (14);
the VA Fee Basis Inpatient and Outpatient datasets,
which capture non-VA care provided to veterans (14);
the VA Laboratory Decision Support System extract,
which includes claims and laboratory results for serum
creatinine measurement (15); and the VA Vital Status
File, which contains validated combined mortality
data from VA, Medicare, and Social Security Adminis-
tration sources (16,17).
IDENTIFICATION OF THE STUDY COHORT. We
identiﬁed patients with newly diagnosed, non-
valvular AF and seen within 90 days in an outpatient
care setting. Figure 1 illustrates our cohort inclusion
criteria: 1) a primary or secondary diagnosis of AF
(International Classiﬁcation of Diseases-9th Revision
[ICD-9] 427.31 or 427.32) associated with an inpatient
or outpatient VA encounter between October 1, 2003,
and September 30, 2008 (VA ﬁscal years 2004 to2008); 2) a second conﬁrmatory diagnosis
between 30 and 365 days after the date of the
index AF diagnosis; 3) at least 1 primary care,
cardiology, women’s health, nephrology,
geriatric, or anticoagulation clinic outpatient
visit in the 90 days after the index date; and
4) receipt of any outpatient prescriptions
within 90 days after the index AF diagnosis.
The requirement of a conﬁrmatory AF diag-
nosis is intended to minimize the impact of
rule-out diagnoses and improve speciﬁcity;
this approach has been previously applied to
Medicare (18,19) and VA (12) studies.
Patients were excluded if they met any of
the following criteria at the index date: 1) a
prior AF diagnosis, deﬁned by any inpatient,
outpatient or Fee Basis AF ICD-9 codes or
Current Procedural Terminology-4th Edition
(CPT-4) codes for catheter or surgical ablation
in the 4 years prior; 2) history of valve disease, repair,
or replacement; 3) thyroid disease; 4) kidney trans-
plant; or 5) cardiac surgery within 30 days.
PRIMARY EXPOSURE VARIABLES AND OUTCOMES. The
primary exposure variable was receipt of outpatient
digoxin during a 90-day exposure ascertainment
window, starting from date of the index AF diagnosis.
The primary outcome was time to death, beginning
from 90 days after index AF diagnosis. Death was
ascertained using VA’s validated Vital Status ﬁle,
which has 97.6% agreement and 98.3% sensitivity for
detection of deaths identiﬁed by the National Death
Index (17). We assumed that patients with no record
of death were alive until September 30, 2011, the last
date for which vital status records from all sources
were fully ascertained.
CLINICAL COVARIATES. We determined baseline
patient comorbidities by calculating a Charlson
comorbidity score (20,21) and by identifying
comorbidity-speciﬁc ICD-9 codes up to 2 years before
the index AF date, using algorithms based on the
Agency for Healthcare Research and Quality’s Clinical
Classiﬁcation System (22). Internal checkingof thedata
indicated no substantial increase in comorbidity
ascertainment by extending the claims window for
more than two years prior to the index date. The
CHADS2 score was calculated using diagnostic
algorithms previously validated in VA data (23,24).
Receipt of concomitant outpatient drug therapies
was ascertained using the same methods as for the
primary exposure.
We estimated glomerular ﬁltration rate (eGFR)
using the Chronic Kidney Disease Epidemiology
Collaboration formula (25). We used the most recent
Cohort identified with AF from FY04-FY08 (N=498,171)
Without AF diagnosis in previous 4 years (N=306,389)
With a confirmatory AF diagnosis between 30 to 365 days
after the first AF diagnosis (N=164,574)
Seen in cardiology, primary care, women’s health clinic,
nephrology, geriatric, or anticoagulation clinic as outpatient
within 90 days after first AF diagnosis (N=161,478)
Seen in cardiology, primary care, women’s health,
nephrology, geriatric, or anticoagulation clinic as an 
outpatient within 90 days after first AF
 diagnosis inside the continental U.S. (N=154,332)
Received any outpatient prescription within 90 days of first
AF diagnosis (N=147,583)
Alive 30 days after first AF diagnosis (N=147,582)
No history of ablation within last 4 years before AF diagnosis
(N=147,549)
Presence of at least 1 creatinine value ≥0.3 mg/dl
between -365 days to +90 days from AF diagnosis
(N=126,123)
Analysis cohort (N=122,465)
With AF diagnosis in previous 4 years (N=191,782)
Without AF diagnosis after 30 days and 365 days
of first AF diagnosis (N=141,815)
Not seen in cardiology, primary care, women’s health clinic,
nephrology, geriatric, or anticoagulation clinic as an outpatient within
90 days after first AF diagnosis (N=3,096)
Seen in cardiology, primary care, women’s health, nephrology,
geriatric, or anticoagulation clinic as an outpatient within 90 days
after first AF diagnosis in non-continental U.S. areas (N=7,146)
Did not receive any outpatient prescription within 90 days of first
AF diagnosis (N=6,749)
Died within 30 days of first AF diagnosis (N=1)
History of EP/surgical ablation (includes SVT ablation) within last 4
years before AF diagnosis (N=33)
Did not have at least 1 creatinine value ≥0.3 mg/dl between 
-365 days to +90 days from AF diagnosis (N=21,426)
History of kidney transplant within last 4 years prior to AF diagnosis
(N=273)
Diagnosis of hyperthyroidism within 365 days before AF diagnosis
(N=399)
Prescription of antithyroid medication within 365 days before AF
diagnosis (N=245)
Cardiac surgery within 30 days before AF diagnosis (N=488)
History of valve disease within last 4 years prior to AF diagnosis
on the basis of ICD-9 codes for mitral valve or aortic valve
insufficiency, stenosis, or replacement (N=1,869)
Less than 90 days of observation time after AF index date (N=723)
FIGURE 1 Consort Diagram
Detailed inclusion and exclusion criteria used to select the cohort of 122,465 patients studied in this analysis. AF¼ atrial ﬁbrillation/atrial ﬂutter;
EP ¼ electrophysiology; FY ¼ ﬁscal year; ICD-9 ¼ International Classiﬁcation of Diseases-9th Revision; SVT ¼ supraventricular tachycardia.
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662outpatient serum creatinine from 365 days before to
90 days after the index AF diagnosis. In the VA
system, isotope-dilution mass spectroscopy (IDMS)-
based calibration was implemented beginning in the
third quarter of 2007. Because GFR can be under-
estimated if creatinine measurements have not been
calibrated to IDMS (26), we therefore adjusted for
non-IDMS standardized creatinine values by sub-
tracting 5% from all creatinine measurements
before ﬁscal year 2008. Kidney function was then
stratiﬁed by eGFR (in ml/min/1.73 m2) into the
following groups: $90; <90 to $60; <60 to $45; <45to $30; <30 to $15; and <15. A separate eGFR group
for dialysis-dependent chronic kidney disease was
also identiﬁed using ICD-9 and CPT-4 codes for
dialysis-related procedures or diagnoses.
STATISTICAL ANALYSIS. We compared differences
in baseline characteristics between digoxin-treated
patients and untreated patients using chi-square
tests for categorical variables and Student t tests for
continuous variables. We performed Cox regression
to estimate the risk of death, ﬁrst modeling an
“intention-to-treat” analysis on the basis of digoxin
receipt, adjusting for age, sex, race, hypertension,
TABLE 1 Baseline Characteristics
Digoxin Prescribed Within
90 Days After AF Diagnosis
Yes
(n ¼ 28,679)
No
(n ¼ 93,786) p Value
Seen in primary care 20,936 (73.0) 68,449 (73.0) 0.96
Age, yrs 71.7  10.2 72.2  10.3 <0.001
Female 434 (1.5) 1,546 (1.7) 0.11
Race, white 24,532 (85.5) 79,918 (85.2) 0.17
Charlson comorbidity index 1.1  1.2 0.91  1.1 <0.001
CHADS2 score group <0.001
CHADS2 0–1 14,536 (50.7) 43,241 (46.1) <0.001
CHADS2 2–3 12,163 (42.4) 43,807 (46.7) <0.001
CHADS2 4–6 1,980 (6.9) 6,738 (7.2) 0.11
Congestive HF 6,099 (21.3) 13,218 (14.1) <0.001
Hypertension 16,010 (55.8) 61,491 (65.6) <0.001
Age $75 yrs 12,934 (45.1) 44,925 (47.9) <0.001
Diabetes 7,949 (27.7) 27,353 (29.2) <0.001
Prior stroke/TIA 1,551 (5.4) 6,009 (6.4) <0.001
Prior MI 1,370 (4.8) 4,149 (4.4) 0.01
eGFR group, ml/min/1.73 m2 <0.001
eGFR $90 3,782 (13.2) 11,673 (12.5) 0.001
eGFR 60–89 14,611 (51.0) 47,299 (50.4) 0.13
eGFR 45–59 6,312 (22.0) 20,464 (21.8) 0.50
eGFR 30–44 3,076 (10.7) 10,207 (10.9) 0.45
eGFR 15–29 727 (2.5) 3,011 (3.2) <0.001
eGFR <15 88 (0.31) 582 (0.62) <0.001
Dialysis 83 (0.29) 550 (0.59) <0.001
eGFR, ml/min/1.73 m2 67.6  19.9 66.6  20.6 <0.001
Cardiovascular medications
Aspirin 4,738 (16.5) 13,973 (14.9) <0.001
Clopidogrel 1,499 (5.2) 4,941 (5.3) 0.78
Aspirin þ clopidogrel 731 (2.6) 2,004 (2.1) <0.001
ACE inhibitor or angiotensin
receptor blockers
17,133 (59.7) 47,471 (50.6) <0.001
Alpha-blockers 464 (1.6) 1,948 (2.1) <0.001
Diuretic agents 16,625 (58.0) 40,422 (43.1) <0.001
Niacin or ﬁbrates 2,384 (8.3) 6,258 (6.7) <0.001
Statins 15,137 (52.8) 49,661 (53.0) 0.61
Warfarin 18,045 (62.9) 50,843 (54.2) <0.001
Antiarrhythmic drugs <0.001
All Class I 585 (2.0) 2,031 (2.2) 0.20
Class III (sotalol/dofetilide) 810 (2.8) 3,364 (3.6) <0.001
Amiodarone 2,849 (9.9) 8,806 (9.4) 0.006
Rate-controlling drugs
All beta-blockers 18,246 (63.6) 53,065 (56.6) <0.001
Metoprolol 11,923 (41.6) 34,884 (37.2) <0.001
Carvedilol 3,331 (11.6) 4,375 (4.7) <0.001
Atenolol 2,735 (9.5) 12,785 (13.6) <0.001
Other 257 (0.90) 1,021 (1.1) 0.01
All calcium-channel blockers 8,742 (30.5) 28,340 (30.2) <0.001
Diltiazem 5,175 (18.0) 12,622 (13.5) <0.001
Verapamil 840 (2.9) 1,866 (2.0) <0.001
Other 2,727 (9.5) 13,852 (14.8) <0.001
Values are n (%) or mean  SD.
ACE ¼ angiotensin-converting enzyme; AF ¼ atrial ﬁbrillation/atrial ﬂutter; eGFR ¼ estimated
glomerular ﬁltration rate; HF ¼ heart failure; MI ¼ myocardial infarction; TIA ¼ transient
ischemic stroke.
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663prior stroke, HF, diabetes, Charlson comorbidity score,
CHADS2 score, cardiovascular medications, antiar-
rhythmic drug therapies, and eGFR stratum.
Next, to account for variable exposure on the basis
of duration and intensity of drug therapy, we per-
formed an adherence-adjusted analysis by quantifying
digoxin exposure by calculating the patient-level
medication possession ratio (MPR) and performing
Cox regression with MPR as a time-varying covariate.
The MPR was calculated as the fraction of total
outpatient days’ supply of digoxin divided by the total
number of days from time of AF diagnosis until date of
death or censoring, truncated at 1.0. The MPR was
adjusted to account for carryover of previous medica-
tion ﬁlls to avoid overestimation of drug supply. If the
patient received different dosages on the same day,
these were considered part of the same prescription.
This approach has been validated (27,28) and used
previously with VA data (29). For all Cox models, the
assumption of proportional hazards was found to be
valid by examining Schoenfeld residuals.
PROPENSITY MATCHING. We also performed a sepa-
rate Cox regression on patients matched by the pro-
pensity scores of digoxin receipt. Propensity scores
were calculated, with receipt of digoxin as the
dependent variable, by using multivariate logistic
regression and baseline characteristics listed in Table 1
as independent variables. We tested pairwise in-
teractions of covariates and retained the terms that
signiﬁcantly improved model ﬁt. Propensity score
balance and overlap were assessed using propensity
score distributions and standardized differences in
observed characteristics. Model ﬁt was assessed using
the Hosmer-Lemeshow goodness-of-ﬁt test and the
C-statistic. Patients receiving the study drug were
matched 1:1 with nonrecipients using nearest-
neighbor matching without replacement. Finally, we
used the Kaplan-Meier method to estimate cumulative
incidence of death in both the full and propensity-
matched cohorts, and log-rank tests to assess differ-
ences between treated and untreated groups.
STRATIFIED AND SUBGROUP ANALYSES. We tested
for modiﬁcation of the association between digoxin
use and mortality using the chi-square test for a series
of potential effect modiﬁers. A log-likelihood ratio
test for nested models with n degrees of freedom,
where n ¼ the number of interaction terms, was
used to assess model ﬁt. Potential effect modiﬁers
included age, sex, presence of HF, prior myocardial
infarction (MI), and concomitant use of warfarin,
beta-blockers, or amiodarone.
SENSITIVITY ANALYSES. We used the method of Lin
et al. (30) to perform a 3-way sensitivity analysis to
CENTRAL ILLUST
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664determine whether observed differences in the risk of
death could be fully explained by unmeasured con-
founders. Using this approach, we calculated the
hazard required of an unmeasured confounder to
explain the result across hypothetical prevalences of
the confounder in the treated and untreated groups.
ROLE OF FUNDING SOURCE. The sponsors were not
involved with study design, data assembly and anal-
ysis, or manuscript preparation. The local institu-
tional review board approved the study. All analyses
were performed using SAS version 9.1 (Cary, North
Carolina) and STATA version 11.0 (College Station,
Texas).
RESULTS
PATIENT POPULATION. A schema of methods and
results are shown in the Central Illustration. The study
cohort included 122,465 patients with a mean age of
72.1  10.3 years; 1.6% were women, and 36.8% of
patients had an eGFR <60 ml/min/1.73 m2 or were on
dialysis. Of these patients, 28,679 (23.4%) received
digoxin during the ﬁrst 90 days after initial AF diag-
nosis (Table 1). In patients receiving digoxin, the
mean MPR was 0.79  0.27, and 70% of digoxin users
were on therapy 1 year after the index date.
Compared with nonrecipients, digoxin recipients
were of similar age but had a higher prevalence of HF
and receipt of beta-blockers, angiotensin receptorRATION The TREAT-AF Study
ciation of digoxin therapy with mortality in patients with newly diagnosed atr
he Retrospective Evaluation and Assessment of Therapies in AF.blockers, antiplatelet therapy, diuretic agents, and
warfarin.
PROPENSITY-MATCHED COHORT. Online Figure 1
shows the propensity distribution and overlap for
recipients and nonrecipients of digoxin in the full
cohort. Using 1:1 nearest-neighbor matching without
replacement, 93.1% of the digoxin-treated group of
patients from the full cohort were matched (Hosmer-
Lemeshow goodness-of-ﬁt test p ¼ 0.70; C-statistic ¼
0.68). Standardized differences of covariates for
matched patients (26,703 in each arm) demonstrated
adequate balance with no standardized differences
>0.10 (31); the highest standardized difference was
0.030 (Online Table 1).
OUTCOMES. Total follow-up time was 353,168
patient-years; 28,723 (23.5%) patients died during the
observation period. Digoxin recipients had higher
unadjusted mortality compared with nonrecipients
(Online Table 2). Digoxin treatment was signiﬁcantly
associated with death in the multivariate Cox
regression model (hazard ratio [HR]: 1.26, 95% conﬁ-
dence interval [CI]: 1.23 to 1.29, p < 0.001) and after
propensity matching (HR: 1.21, 95% CI: 1.17 to 1.25, p <
0.001) (Table 2). The results were similar and signiﬁ-
cant when including digoxin MPR as a time-varying
covariate with and without propensity matching
(HR: 1.31, 95% CI: 1.27 to 1.36, p < 0.001 for full cohort;
1.18, 95% CI: 1.10 to 1.27, p < 0.001 for propensityial ﬁbrillation/atrial ﬂutter (AF). CI ¼ conﬁdence interval; HR ¼ hazard
TABLE 2 Multivariate and Propensity-Matched Cox Regression Results
Model
Full Cohort Propensity-Matched Cohort
(n ¼ 122,465) p Value (n ¼ 53,406) p Value
Unadjusted 1.37 (1.33–1.40) <0.001 — —
Age, sex, race 1.40 (1.37–1.44) <0.001 — —
Full model*
All patients 1.26 (1.23–1.29) <0.001 1.21 (1.17–1.25) <0.001
Adherence (MPR)-
adjusted†
1.31 (1.27–1.36) <0.001 1.18 (1.10–1.27) <0.001
eGFR group,
ml/min/1.73 m2‡
eGFR $90 1.37 (1.25–1.51) <0.001 1.31 (1.17–1.46) <0.001
eGFR 60–89 1.24 (1.19–1.29) <0.001 1.22 (1.16–1.28) <0.001
eGFR 45–59 1.26 (1.20–1.33) <0.001 1.21 (1.14–1.29) <0.001
eGFR 30–44 1.20 (1.13–1.29) <0.001 1.14 (1.05–1.23) 0.001
eGFR 15–29 1.26 (1.13–1.41) <0.001 1.21 (1.04–1.40) 0.01
eGFR <15 1.41 (1.04–1.92) 0.03 1.20 (0.79–1.83) 0.84
Dialysis 1.39 (0.996–1.93) 0.053 0.79 (0.53–1.18) 0.25
Values are hazard ratio (95% conﬁdence interval). *For full cohort, full models were adjusted for
age, sex, race, hypertension, stroke, HF, diabetes mellitus, CHADS2 score, Charlson comorbidity
score, beta-blockers, diuretic agents, antiplatelet agents, warfarin, statins, niacin/ﬁbrates, ACE
inhibitors/angiotensin receptor blockers, antiarrhythmic drug therapies, and eGFR group. †Full
adherence (MPR)-adjusted model was created by adjusting for digoxin medication possession
ratio (MPR) from date of ﬁrst AF diagnosis to date of death or censoring, as a time-varying
exposure. Also adjusted for age, sex, race, hypertension, stroke, HF, diabetes mellitus, CHADS2
score, Charlson comorbidity score, digoxin, beta-blockers, diuretic agents, anti-platelet agents,
warfarin, statins, niacin/ﬁbrates, ACE inhibitors/angiotensin receptor blockers, antiarrhythmic
drug therapies, and eGFR group. ‡p Values for interaction were not signiﬁcant (p > 0.10) for eGFR
as a potential effect modiﬁer in either full or propensity-matched cohort.
Abbreviations as in Table 1.
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FIGURE 2 Cumulative Incidence of Death in the
Propensity-Matched Cohort
The ﬁgure shows the cumulative incidence of death, comparing
treated and untreated patients in the propensity matched cohort,
with curves estimated using the Kaplan-Meier method. Differ-
ences in treated and untreated groups were assessed using the
log-rank test. AF ¼ atrial ﬁbrillation/atrial ﬂutter.
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665matched cohort) (Table 2). Figure 2 shows the cumu-
lative incidence of death in the propensity-matched
cohort. Cumulative incidence of death was higher in
the digoxin-treated patients versus the untreated
group (p < 0.001).
RELATIONSHIP TO KIDNEY FUNCTION. With multi-
variate adjustment and propensity matching, digoxin
was associated with a signiﬁcant increase in risk of
death among nearly all strata of eGFR, except dialysis
patients (Table 2). However, there was no evidence of
effect modiﬁcation present across strata of kidney
function (p ¼ 0.76).
SUBGROUP ANALYSIS. Multivariate and propensity-
matched analyses are shown for 9 clinically relevant
subgroups in Table 3. Overall, subgroup ﬁndings were
similar to the point estimates for the full and
propensity-matched cohorts. There was evidence of
possible effect modiﬁcation in the full cohort and
increased risk in patients with prior MI (pinteraction ¼
0.002 in the full cohort; pinteraction ¼ 0.077 in the
propensity-matched cohort). In all other subgroups,
tests for interaction were not signiﬁcant (p # 0.10) in
full and propensity-matched analyses.
SENSITIVITY TO UNMEASURED CONFOUNDING. We
performed an analysis to determine whether an un-
measured confounder (or set of confounders) can
explain the propensity-matched HR of digoxin for
death (Fig. 3). The curves compare the hypothetical
prevalence of the unmeasured confounder(s) within
the digoxin-treated group (x-axis) and within the un-
treated group (curves for 5%, 10%, 20%, 30%, and
40%), showing the hypothetical HR (y-axis) for all-
cause mortality that would need to be associated
with this confounder. For example, if an unmeasured
confounder was present in 30% of untreated patients
(Fig. 3, orange line) and in 50%, 60%, or 80% of
digoxin-treated patients (x-axis), then the HR required
for the confounder to account for the observed
difference (i.e., to shift the upper 95% HR conﬁdence
interval to 1.00) would be 2.5, 1.9, and 1.7, respectively.
As an example of an unmeasured confounder,
suppose that patients treated with digoxin had
greater frailty and that this was not captured with
the current variables. If frailty was present in 5% of
untreated patients (Fig. 3, red line) and in 20% of
digoxin-treated patients, then frailty could explain the
observed difference only if frailty independently
increased the risk of death by a factor (HR) of 2.4.
DISCUSSION
The present study was designed to evaluate the
association of digoxin therapy with mortality inpatients with newly diagnosed AF. With 122,465
subjects and 353,168 person-years of follow-up, our
analysis includes the largest AF cohort to date
addressing this issue, demonstrating that treatment
TABLE 3 Subgroup Analysis: Association of Digoxin With Mortality
Full Cohort* Propensity-Matched Cohort†
HR (95% CI)
p Value for
Interaction HR (95% CI)
p Value for
Interaction
Male 1.26 (1.23–1.29) NS 1.21 (1.17–1.25) NS
Female 1.23 (0.98–1.55) NS 1.31 (0.997–1.72) NS
Age $65 yrs 1.24 (1.21–1.28) NS 1.21 (1.17–1.26) NS
Age <65 yrs 1.37 (1.27–1.48) NS 1.27 (1.16–1.39) NS
Previous diagnosis of HF 1.29 (1.23–1.36) NS 1.28 (1.21–1.36) NS
Previous diagnosis of MI‡ 1.49 (1.34–1.67) 0.002 1.45 (1.26–1.66) 0.077
Treated with warfarin 1.27 (1.23–1.32) NS 1.21 (1.16–1.26) NS
Treated with beta-blocker 1.28 (1.23–1.32) NS 1.24 (1.19–1.29) NS
Treated with amiodarone 1.27 (1.17–1.38) NS 1.26 (1.14–1.39) NS
*Adjusted for age, sex, race, hypertension, stroke, HF, diabetes, CHADS2 score, Charlson comorbidity score, beta-
blockers, diuretic agents, antiplatelet agents, warfarin, statins, niacin/ﬁbrates, ACE inhibitors/angiotensin re-
ceptor blockers, antiarrhythmic drug therapies, and eGFR. †Covariates considered for the propensity-matched
analysis include: age, sex, race, Charlson comorbidity index, CHADS2 0 to 1, CHADS2 2 to 3, CHADS2 4 to 6,
mean CHADS2 score, HF, hypertension, diabetes, prior stroke/TIA, eGFR $90, eGFR 60 to 89, eGFR 45 to 59,
eGFR 30 to 44, eGFR 15 to 29, eGFR <15, dialysis, diuretic agents, niacin or ﬁbrates, statins, warfarin, all beta-
blockers, antiplatelet agents, ACE inhibitors/angiotensin receptor blockers, and antiarrhythmic drug therapies. A
relevant covariate was removed from the model when that variable deﬁned the subgroup being analyzed. No p
values for interaction were signiﬁcant (p > 0.10) for potential effect modiﬁers in propensity-matched analyses.
‡p Value for interaction was signiﬁcant (p # 0.05) for only 1 potential effect modiﬁer: prior myocardial infarction
(p ¼ 0.002) in the full cohort.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; NS ¼ not signiﬁcant if p >0.10 for interaction term; other ab-
breviations as in Table 1.
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666with digoxin is associated with increased risk of
mortality. These observations were consistent across
all subgroups and were independent of drug adher-
ence, kidney dysfunction, HF, or concomitant20 60 8040
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FIGURE 3 Effect of Unmeasured Confounding Factors
This sensitivity analysis shows how powerful an unmeasured
confounder (or set of confounders) would have to be to explain
the increased hazard of death associated with digoxin. The hy-
pothetical prevalence of an unmeasured confounder in the
treated group (x-axis) is graphed against the hypothetical prev-
alence in the untreated group (colored curves associated with
5%, 10%, 20%, 30%, and 40%, respectively). The y-axis rep-
resents the hypothetical hazard ratio of the unmeasured
confounder required to fully explain the mortality difference
observed between the treated and untreated groups for digoxin.therapy with beta-blockers or amiodarone. The
risk may be increased in patients with prior MI.
These ﬁndings challenge the current cardiovascular
society guidelines, which give Class I and Class IIa
recommendations for the use of digoxin as an adjunct
to rate control monotherapy (2,3).
DIGOXIN THERAPY AND MORTALITY IN AF. Surpris-
ingly, few studies have evaluated the safety of
outpatient digoxin in AF (32). The Stockholm Cohort
study of 2,824 patients with AF found that digoxin
was not associated with mortality after adjustment or
propensity matching, although unadjusted mortality
was markedly higher in digoxin-treated patients
(8). An AFFIRM (Atrial Fibrillation Follow-Up Inves-
tigation of Rhythm Management) study secondary
analysis demonstrated that digoxin exposure was
associated with mortality (9). The point estimate was
higher (HR: 1.41, 95% CI: 1.19 to 1.67) than in our
study, which may be due to differences in patient
populations, treatment options, or methods. The
AFFIRM study predated contemporary treatment for
HF, coronary disease, and stroke prevention. The
AFFIRM study also used a propensity score as a co-
variate, which is less effective at balancing multiple
covariates compared with propensity matching,
particularly when match rates are high as in our
cohort. Also, both of these studies were of patients
with prevalent AF, which can introduce substantial
survival or “immortal person-time” bias. Our study
design, which is restricted to only patients with
newly diagnosed AF, greatly minimizes such bias.
Amore recent post-hoc analysis on the AFFIRM trial
conducted by Gheorghiade et al. (11) attempted to
address a few of these limitations with propensity
matching, although still in a prevalent AF cohort. This
AFFIRM study reanalysis found no association be-
tween digoxin exposure and mortality (HR: 1.06; 95%
CI: 0.83 to 1.37; p ¼ 0.64) after matching a total of 1,756
patients on propensity scores. However, patients from
the AFFIRM trial were predominantly elderly, asymp-
tomatic, or minimally symptomatic trial participants.
In contradistinction, our data represent the total
number of patients with new AF from the full denom-
inator of the Veterans Affairs healthcare system. With
30 times as many propensity-matched patients, the
present study also has greater statistical power.
The DIG (Digitalis Investigation Group) trial, which
randomized patients with HF to digoxin, demon-
strated no mortality difference but a decrease in HF
hospitalizations compared with placebo (5). However,
this trial excluded patients with AF and predated
contemporary HF therapy, whereas background
beta-blocker and angiotensin blocker use was
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE 1: Digoxin is
widely used to control the ventricular rate in patients with AF,
but the evidence supporting safety and efﬁcacy are limited.
COMPETENCY IN MEDICAL KNOWLEDGE 2: In patients
with recently identiﬁed AF, treatment with digoxin was associ-
ated with an increased risk of death, independent of drug
adherence, kidney function, cardiovascular comorbidities, or
concomitant therapies.
COMPETENCY IN PATIENT CARE: Physicians should consider
alternatives to digoxin in managing patients with AF.
TRANSLATIONAL OUTLOOK: Prospective studies are needed
to conﬁrm the ﬁndings of this observational report and explore
the mechanisms responsible for the increased risk of mortality in
patients with AF treated with digoxin.
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667substantially higher in our study. A more recent
observational analysis of 2,891 digoxin users in the
Kaiser Permanente healthcare system with incident
HF (not AF) did demonstrate an increased risk of
death (33).
Finally, the subgroup interaction of digoxin in
patients with prior MI is intriguing. However, it
should be viewed as hypothesis-generating, particu-
larly given the multiple subgroups evaluated.
ROLE OF UNIDENTIFIED CONFOUNDING. The
observational nature of this study cannot preclude
the presence of unidentiﬁed confounders. In partic-
ular, confounding by indication is the greatest con-
cern, because unmeasured variables such as frailty,
HF severity, and ejection fraction (which themselves
are associated with death), could led to treatment
selection with digoxin. Our sensitivity analysis (Fig. 3)
evaluates the impact of unmeasured confounders.
The results indicate that an unmeasured confounder,
such as frailty, would require a fairly high hazard of
death (>2.0 in most cases) and be at least twice as
prevalent in the digoxin-treated patients.
However, it is well established that patients with
frailty or severe HF have poorer drug adherence. We
therefore did adjust for drug adherence, and results
of the adherence-adjusted analyses were consistent
with the overall results. A secondary data analysis
from the SPORTIF (Stroke Prevention using an ORal
Thrombin Inhibitor in atrial Fibrillation) III and V
studies, which also adjusted for blood pressure and
left ventricular dysfunction, demonstrated a mortal-
ity HR of 1.53 for digoxin (34). Therefore, we believe
that unmeasured confounding of sufﬁcient severity
to explain our ﬁndings is not likely.
STUDY LIMITATIONS. Our study is nonrandomized.
The analysis cohort predominantly consists of male
veterans, which limits generalizability of ﬁndings to
women, although we did examine the mortality asso-
ciation with digoxin among women in subgroup anal-
ysis.Wewere unable to evaluate treatment dose on the
basis of available data, although the mortality associ-
ation was consistent across all strata of renal function
and after adjustment for medication adherence.
Because AF is a progressive disease, the choice to
include patients with new (incident) AF would be
expected to minimize survival bias on the basis of
duration of AF, but could also limit generalizability of
our ﬁndings in prevalent AF cohorts. Additionally,
survival bias could still occur if patients received the
exposure or confounding therapies for other condi-
tions before the index AF date.
We also could not measure HF severity, on the
basis of symptom class, ejection fraction, or HFhospitalizations. Differences in HF severity could
be a source of unidentiﬁed confounding, which we
attempted to address through our sensitivity analysis.
Although we speciﬁed adherence to digoxin as a time-
varying covariate, there is a possibility that time-
varying confounders, such as discontinuation of
other cardiovascular medications, could inﬂuence
survival.
We used all-cause mortality rather than cause-
speciﬁc mortality, which could prevent a more
meaningful determination of how drug exposure may
have led to death. However, in 1 AFFIRM substudy,
the magnitude of the HRs for digoxin was similar for
all-cause, cardiovascular, and arrhythmic death (9).
Furthermore, the recent propensity-matched AFFIRM
substudy by Gheorghiade et al. (11) used all-cause
mortality as the study endpoint, although there was
no signiﬁcant association with digoxin in their
ﬁndings.
CONCLUSIONS
In this large, retrospective cohort of patients with
newly diagnosed AF, treatment with digoxin was
independently associated with mortality, regardless
of age, sex, kidney function, heart failure status,
concomitant therapies, or drug adherence.
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